Elevai Labs (ELAB) said Thursday that its Elevai Biosciences subsidiary filed two patent applications for its lead candidate, EL-22, to treat muscle loss in obese patients.
The applications cover both standalone and combination therapies with GLP-1 receptor agonists, according to the company.
A phase 1 study of EL-22 in South Korea has been completed, showing safety and tolerability in healthy volunteers, Elevai said, adding it plans to evaluate the investigational drug's efficacy in combination with GLP-1 to counteract muscle wasting associated with the medications while promoting weight loss.
Shares of the drug developer rose more than 30% in recent premarket activity.
Price: 0.1109, Change: +0.03, Percent Change: +30.16
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。